Carola H. Ries

Penzberg, BY 82377, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies.

Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies.

Journal: International journal of molecular sciences

Published: November 28, 2022

Tumor-associated macrophages promote intratumoral conversion of conventional CD4+ T cells into regulatory T cells via PD-1 signalling.

Tumor-associated macrophages promote intratumoral conversion of conventional CD4+ T cells into regulatory T cells via PD-1 signalling.

Journal: Oncoimmunology

Published: April 28, 2022

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.

Journal: Journal for immunotherapy of cancer

Published: March 08, 2022

Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages.

Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages.

Journal: Cancer research

Published: January 13, 2022

Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes.

Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes.

Journal: Frontiers in immunology

Published: April 02, 2021

Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma.

Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma.

Journal: Cancers

Published: March 02, 2021

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.

Journal: Journal for immunotherapy of cancer

Published: September 21, 2020

Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition.

Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition.

Journal: Science translational medicine

Published: June 22, 2020

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.

Journal: Science translational medicine

Published: June 04, 2020

Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.

Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 29, 2020

PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor.

PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor.

Journal: Clinical pharmacology and therapeutics

Published: April 08, 2020

The Tumor Milieu Promotes Functional Human Tumor-Resident Plasmacytoid Dendritic Cells in Humanized Mouse Models.

The Tumor Milieu Promotes Functional Human Tumor-Resident Plasmacytoid Dendritic Cells in Humanized Mouse Models.

Journal: Frontiers in immunology

Published: March 05, 2020

Showing 1-12 of 44

Last Updated: 09/26/2026